E. Ohman J:or Asset Management
ESPR icon

E. Ohman J:or Asset Management’s Esperion Therapeutics ESPR Stock Holding History

E. Ohman J:or Asset Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-15,738
Closed -$632K – 381
2019
Q1 		$632K Sell
15,738
-14,771
-48% -$663K 0.04% 214
2018
Q4 		$1.4M Sell
30,509
-45,768
-60% -$2.21M 0.1% 118
2018
Q3 		$3.38M Buy
76,277
+17,120
+29% +$786K 0.22% 78
2018
Q2 		$2.32M Buy
+59,157
New +$2.99M 0.17% 101

Other funds holding ESPR

Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

E. Ohman J:or Asset Management's ESPR Position: Q2 2019 in Review

E. Ohman J:or Asset Management sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 15,738 shares — an estimated $632K sold.

E. Ohman J:or Asset Management first reported a position in ESPR in Q2 2018 and held it in 4 quarters. The position peaked at $3.38M in Q3 2018. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • E. Ohman J:or Asset Management reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • E. Ohman J:or Asset Management sold 15,738 Esperion Therapeutics shares in Q2 2019, an estimated $632K.
  • E. Ohman J:or Asset Management first reported a position in Esperion Therapeutics in Q2 2018 and held it in 4 quarters.
  • E. Ohman J:or Asset Management's Esperion Therapeutics position peaked at $3.38M in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on E. Ohman J:or Asset Management's 13F filing for Q2 2019, filed 5 Apr 2024.